Regeneron Pharmaceuticals REGN announces its next round of earnings this Thursday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.
Earnings and Revenue
Regeneron earnings will be near $4.70 per share on sales of $1.56 billion, according to analysts.
Regeneron earnings in the same period a year ago was $4.17. Quarterly sales came in at $1.47 billion. The Wall Street estimate would represent a 12.71 percent increase in the company's earnings. Revenue would be up 6.12 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | 4.32 | 4.52 | 3.85 | 3.16 |
| EPS Actual | 4.67 | 5.23 | 3.99 | 4.17 |
Stock Performance
Over the last 52-week period, shares are down 27.66 percent. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release. Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. Analysts seem to have settled on a Neutral rating with Regeneron. The strength of this rating has maintained conviction over the past three months.
Conference Call
Regeneron's Q2 conference call is scheduled to begin at 8:30 a.m. ET and can be accessed here: https://www.regeneron.com/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
